YourLawyer.com® 1-800-LAW-INFO (1-800-529-4636)
Injured by Aranesp?
Aranesp (generic: darbepoetin alfa) is approved to treat anemia caused by chemotherapy. Anemia is a common side effect of chemotherapy, which can damage the production of red blood cells. In anemia, the blood is lacking in healthy red blood cells, which transport oxygen to organs. The FDA approved Aranesp on September 17, 2001.On January 14, 2005 Amgen and the FDA sent letters to doctors advising them of a revision to the warning label for Aranesp. Two new studies with other drugs in the same class of Aranesp, known as erythropoietic drugs, have shown that using the drugs at higher-than-recommended doses increases the risk of adverse effects including blood clots and death.
Although the studies were conducted with other drugs (Eprex and NeoRecormon), Amgen has incorporated this information into the prescribing information for Aranesp to alert doctors to these potential risks.
Other life threatening side effects of Aranesp include cardiac arrest; hypertension; vascular thrombosis and convulsions.
If you or a loved one took Aranesp and suffered side effects, please fill out the form at the right for a free case evaluation by a qualified drug side effects attorney.
AranespRSS Feed
FDA Says Another Safety Review of Anemia Drugs in the Works
Jan 7, 2010 | Parker Waichman Alonso LLP
Anemia drugs Procrit, Epogen and Aranesp are slated to undergo another safety review, following the publication of a clinical trail that linked one of them to an increased risk of stroke.According to The New York Times, that study, called “Treat” was published in October in the New England Journal of Medicine. The goal of Treat was to see if using Aranesp to increase the red blood cell levels of people with diabetes and kidney disease would prevent death and cardiovascular problems....
Procrit, Similar Drugs Linked to Increased Death Risk By Two More Studies
May 5, 2009 | Parker Waichman Alonso LLP
Two more studies have found that anemia drugs like Epogen, Procrit and Aranesp raise the risk of death among cancer patients. Despite known safety risks, drugs like Procrit continue to be used because it is believed that they help reduce the number of blood transfusions some cancer patients need, while improving quality of life. According to a report on MedicineNet.com, these two studies may raise questions about that theory.Epogen, Procrit and Aranesp are known as...
Amgen Ends Controversial Aranesp Marketing Practices
Aug 29, 2008 | Parker Waichman Alonso LLP
The maker of Aranesp is halting marketing practices that critics said encouraged over-use of the anemia drug. Criticism of the policies, in which Amgen paid rebates to doctors for the purchase of Aranesp, had grown along with questions about the drug's safety. Aranesp is an erythropoiesis-stimulating agent (ESA). Two other ESA's, Epogen and Procrit, are also currently available. All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho...
More than 44,000 Vials of Procrit Recalled
Aug 6, 2008 | Parker Waichman Alonso LLP
Procrit is being recalled by Johnson & Johnson subsidiary Ortho Biotech. According to the company's recall notice, the action is necessary because cracks in the necks of a small number of Procrit vials were discovered upon post-manufacturing inspection.The Procrit recall involves approximately 44,292 vials of lot P114942A distributed between April 15, 2008 and July 17, 2008. The recalled Procrit vials were available in the following packaging configurations:Individual...
FDA Forces New Labeling for Procrit, Aranesp and Epogen
Jul 31, 2008 | Parker Waichman Alonso LLP
Federal regulators have decided that the anemia drugs Aranesp, Epogen and Procrit need to have additional safety-related changes to their labels. The changes mandated by the Food & Drug Administration (FDA) would restrict the use of the drugs in some cancer patients.Procrit, Aranesp and Epogen are known as erythropoiesis-stimulating agent (ESA). All are made by Amgen, but Procrit is sold by Johnson & Johnson subsidiary Ortho Biotech under a licensing agreement....
Aranesp
Quick Facts
Aranesp Reference Guide
Generic Name
Darbepoetin alfa
Date Approved
September 17, 2001
Manufacturer
Amgen, Inc
Status
On the market
1/14/05 updated label
Approved Uses
Anemia
Serious Side Effects
Blood clots
Hypertension
Cardiac arrest
Acute Myocardial Infarction
Vascular Thrombosis
Convulsions
Related Topics
Blood Clots
Defective Drugs
Diseases
Darbepoetin alfa
Date Approved
September 17, 2001
Manufacturer
Amgen, Inc
Status
On the market
1/14/05 updated label
Approved Uses
Anemia
Serious Side Effects
Blood clots
Hypertension
Cardiac arrest
Acute Myocardial Infarction
Vascular Thrombosis
Convulsions
Related Topics
Blood Clots
Defective Drugs
Diseases
News Feeds
WE ALSO OFFER OUR FIRM NEWS AS RSS/XML FEEDS.
LEARN MORE ABOUT RSS